Clinical Trial Search

Primary: Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) — 10; 10; 8; 3 Participants

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to…

Primary: Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population — 67.7; 29.7 percentage of patients — p=<0.0001

Primary: Improvement in Myasthenia Gravis (MG) Symptoms as Measured by the Mean Change in Quantitative Myasthenia Gravis (QMG) Total Score. — -4.6; -2.7 units on a scale

Primary: Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score — -5.5; -6.0; -3.2 score on a scale — p==0.0941

Primary: Percentage of Patients With Quantitative MG Score (QMG) Score ≤ 4 and a Daily Prednisolon Dose of ≤ 10mg at 16 Weeks After Administration of Study Drug/Placebo. — 17; 6…

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability — 11; 12; 9; 12 Participants

Primary: To Determine the Effect of Acupuncture on Quality of Life in Patients With MG — 10.8; 9.4; 3.6; 8.3 score on a scale

Primary: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)…

Primary: Change From Baseline In Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score At Week 26 — -3.1; -1.4 units on a scale — p==0.0009

Primary: Percent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39 — 60.0; 63.3; 58.6; 60.7 percentage of subjects…

Primary: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score to Visit 9 — -1.2; -1.8 scores on a scale — p==0.221

Primary: Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24 — -2.37; -4.21 Units on a scale — p=0.256

Primary: Number of AEs, SAEs and AESIs — 3325; 107; 420 events

Primary: Change From Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score — -0.784; -3.370; -3.403 units on a scale — p=<0.001

Primary: Change From Baseline in the QMG Total Score at Week 26 Regardless of Rescue Treatment — -6.1 units on a scale — p=0.0004

Primary: Mean of the Average MG-ADL Total Score Change From Baseline During the Visit of Week 1 Through Week 21 by Regimen Arm — -5.13; -4.61 Score on a scale

Primary: Count Of Participants With Treatment-Emergent Adverse Events — 55; 59; 3; 5 Participants

Primary: Mean Change From Baseline in the Quantitative Myastenia Gravis (QMG) Score at Week 25. Posterior Median Was Used as Measure Type. — -4.07; -2.93 score

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 76.0; 78.6 percentage of participants

Primary: Total Prednisone Dose Area Under the Curve — 2996.6; 3484.7 mg*Months — p=0.26

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in…

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 78.4; 94.1 percentage of participants

Primary: Time-weighted Average Quantitative Myasthenia Gravis Weakness Score Over 3 Years — 6.15; 8.99 units on a scale

Primary: Change in Quantitative Myasthenia Gravis (QMG) Scale Score — -6.4 score on a scale — p=<0.001

Primary: Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the…

Primary: Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 5; 0 Participants

Primary: Percent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set) — -66.4; -62.2 percent — p=< 0.0001

Primary: Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score — -2.30; -4.39 score on a scale — p=<0.001

Primary: Proportion of Patients Whose Quantitative Myasthenia Gravis Scores Are Increased by no More Than 3 Points at the End of the SCIg Treatment Phase — 0.864 proportion of…